Sanofi Gets CDSCO Panel Nod To Market Avalglucosidase Alfa Powder for Pompe Disease
New Delhi: Granting a local Phase III and Phase IV clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has given its nod to pharmaceutical major Sanofi Healthcare India to import and market Avalglucosidase Alfa Powder for concentrate for the solution of infusion indicated for the treatment of long-term...
New Delhi: Granting a local Phase III and Phase IV clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has given its nod to pharmaceutical major Sanofi Healthcare India to import and market Avalglucosidase Alfa Powder for concentrate for the solution of infusion indicated for the treatment of long-term enzyme replacement therapy for the treatment of patients with Pompe disease.
This came after Sanofi presented a proposal to import and market Avalglucosidase alfa powder for concentrate for solution for infusion (10 mg/ml) indicated for the treatment of long-term enzyme replacement therapy for patients with Pompe disease, along with a request to waive Phase III and Phase IV clinical trials in the country.
Pompe disease (also known as acid-maltase disease and glycogen storage disease II) is a rare genetic disorder that causes progressive weakness to the heart and skeletal muscles. It is caused by mutations in a gene that makes an enzyme called acid alpha-glucosidase (GAA), which the body uses to break down glycogen, a stored form of sugar used for energy.
Enzyme replacement therapy can help improve muscle tone and reduce glycogen storage in individuals with Pompe disease.
Avalglucosidase alfa is a lysosomal glycogen-specific enzyme that is used to treat patients one year of age and older with late-onset Pompe disease, or lysosomal acid alpha-glucosidase (GAA) deficiency.
Enzyme replacement therapy using avalglucosidase alfa aims to restore the missing GAA enzyme. Avalglucosidase alfa is a hydrolytic lysosomal glycogen-specific recombinant human GAA enzyme that is conjugated with multiple synthetic bis-mannose-6-phosphate (bis-M6P) tetra-mannose glycans for enhanced targeting to skeletal muscles. The M6P of avalglucosidase alfa binds to cation-independent mannose-6-phosphate receptor (CI-MPR) on the cell surface with high affinity, which allows drug uptake into cells. Avalglucosidase alfa is internalized and transported into lysosomes to undergo proteolytic cleavage. It then exerts GAA enzymatic activity to cleave glycogen.
At the recent SEC meeting for endocrinology and metabolism held on 19th and 20th January 2023, the expert panel reviewed the proposal to import and market Avalglucosidase alfa powder for concentrate for solution for infusion (10mg/ml) and the request for waiver of Phase III & IV clinical trial in the country, presented by the drug major Sanofi.
In the above meeting, the expert panel noted that the drug falls under the orphan drug category and proposed indication is a rare disease.
The committee also noted that the drug has been granted orphan drug status in US, Australia, Switzerland, Japan and Malaysia and approved in 13 countries including USA, EU, UK, Japan, Canada, Switzerland and Australia.
After detailed deliberation, the committee recommended the grant of permission to import and market the drug with waiver of local Phase III & IV clinical trial in the country.
Also Read:Eli Lilly gets CDCSO panel nod to import, market Galcanezumab
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd